Navigation Links
ERT (eResearchTechnology, Inc.) and Integrium, LLC Form Alliance to Deliver Integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring Services

PHILADELPHIA, Jan. 30 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (ERT), (Nasdaq: ERES), and Integrium, LLC announced today their alliance to provide integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring centralized core laboratory services to clinical trial sponsors and managers worldwide.

eResearchTechnology is a leading provider of centralized electrocardiographic (ECG), eClinical technology, ePRO, and other services to the biopharmaceutical , medical device, and related industries. Integrium is a cardiovascular and metabolic focused clinical research organization (CRO) offering a full range of clinical development services, including Ambulatory Blood Pressure Monitoring (ABPM) centralized core laboratory services.

Under the agreement, ERT and Integrium will deliver a combined solution to meet the increased demand for centralized cardiac safety and ABPM services during clinical trials. The partnership will offer integrated services from project planning and set-up through study conduct, management, and data delivery for primary and secondary Cardiac clinical trial endpoints.

Integrium will provide a full range of ABPM supporting services to include robust & reliable equipment, proprietary analysis software, global on-demand 24/7 attended call center and scientific leadership. ERT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPERT 2.0 workflow-enabled data management system.

"This alliance addresses a growing need in clinical research to offer comprehensive, best in class services in these two closely related areas of clinical study," said Michael McKelvey, President and CEO of ERT. "While many sponsors recognize and source each company for its respective area of expertise, customers increasingly seek consolidation and streamlining in all phases of a clinical trial. ERT and Integrium approach the market in the same way -- focusing on scientific excellence, providing a quality product, and client satisfaction. We are both metrics driven and process oriented to ensure on-time, on-budget, reliable data delivery on a global scale."

"Clinical trial sponsors have a strategic need to deliver accurate, cost-effective results in less time. They need therapeutic specialists with expertise they can trust. This partnership leverages the world's most advanced cardiovascular specific technologies and clinical research specific services from each company into one unified source, reducing costs and accelerating time to market for our Sponsors," commented David Smith, MD, co-founder and Chief Medical Officer of Integrium.

About Integrium

Integrium is a cardiovascular and metabolic focused clinical research organization with an unrivaled reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical, biotechnology and diagnostic companies look to Integrium for a complete range of customized Phase I - Phase IV programs in cardiovascular and metabolic therapeutic areas. Integrium offers a broad range of clinical development services which include project management, medical and clinical monitoring, investigator and patient recruitment, site management, biostatistics, data management, medical safety and pharmacovigilance, quality assurance, regulatory affairs, and medical writing services In addition, Integrium has both an in-house Phase 1 unit and Ambulatory Blood Pressure Monitoring (ABPM) centralized core laboratory services. Combining its Integrium Clinical Excellence (ICE) operational methodology and therapeutic expertise leads sponsors to more confident, better-informed drug development decisions. Integrium is headquartered in Tustin, California, with operational offices in Bedminster, New Jersey and Johannesburg, South Africa. For more information please visit

About ERT

Based in Philadelphia, Pa, ERT (eResearchTechnology, Inc.) ( is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, 2008 financial guidance, involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

EXPERT(R) is a registered trademark of eResearchTechnology, Inc.

Integrium is a trademark of Integrium, LLC.

SOURCE eResearchTechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
2. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
3. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Progeniq Joins Microsoft in Bio IT Alliance
6. Campbell Alliance Managed Markets Practice to Take Leadership Role at CBIs Formulary and Reimbursement Conference
7. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
8. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
9. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
10. Campbell Alliance Named Best Place to Work by Triangle Business Journal
11. Campbell Alliance Business Development Practice to Moderate Two Workshops at LES Annual Meeting in Vancouver
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use ... promoted Melanie Aregger to serve as Chief Operating Officer. , Having joined ... management team and was promoted to Head of InSphero Diagnostics in 2014. ...
(Date:11/24/2015)... 24, 2015 Capricor Therapeutics, Inc. ... the discovery, development and commercialization of first-in-class therapeutics, today ... Officer, is scheduled to present at the 2015 Piper ... a.m. EST, at The Lotte New York Palace Hotel ... . --> . ...
(Date:11/24/2015)... and NEW YORK , November 24, 2015 ... by Bristol-Myers Squibb in a European ... Squibb Company in which the companies will work closely ... and other areas of unmet medical need. The collaboration is ... 5, the latest LSP fund. This is the first investment ...
Breaking Biology Technology:
(Date:11/20/2015)... , November 20, 2015 ... company focused on the growing mobile commerce market and ... Gino Pereira , was recently interviewed on ... will air on this weekend on Bloomberg Europe ... America . --> NXTD ) ("NXT-ID" or ...
(Date:11/19/2015)... VIEW, Calif. , Nov. 19, 2015  Based ... market, Frost & Sullivan recognizes BIO-key with the 2015 ... Leadership. Each year, Frost & Sullivan presents this award ... product line catering to the needs of the market ... the product line meets and expands on customer base ...
(Date:11/19/2015)... , Nov. 19, 2015  Although some 350 companies ... dominated by a few companies, according to Kalorama Information. These ... 51% of the market share of the 6.1 billion-dollar ... The World Market for Molecular Diagnostic s .    ... market is still controlled by one company and only ...
Breaking Biology News(10 mins):